C5 and paroxysmal nocturnal hemoglobinuria: In light of this, there is a need for a more comprehensive understanding of the economic and clinical burden of patients with PNH receiving treatment with C5 inhibitors, who may continue to experience ongoing disease activity, using more recent real-world data and larger sample sizes.